Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BBT-401
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Bridge Biotherapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Bridge Biotherapeutics Becomes BaseLaunch's First Asia Pacific Partner
Details : BBT-401, the first-in-class Pellino-1 inhibitor for treatment of ulcerative colitis, is currently in Phase II in the US, and BBT-877, an autotaxin inhibitor to treat various fibrosing interstitial lung diseases including idiopathic pulmonary fibrosis (IP...
Brand Name : BBT-401
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 15, 2020
Lead Product(s) : BBT-401
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Bridge Biotherapeutics
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?